Soleus Capital Management, L.P. Bei Gene, Ltd. Transaction History
Soleus Capital Management, L.P.
- $1.18 Billion
- Q3 2024
A detailed history of Soleus Capital Management, L.P. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 82,750 shares of BGNE stock, worth $18.1 Million. This represents 1.58% of its overall portfolio holdings.
Number of Shares
82,750
Previous 137,700
39.91%
Holding current value
$18.1 Million
Previous $19.6 Million
5.43%
% of portfolio
1.58%
Previous 1.99%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
253Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.31 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.41 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.13 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$1.09 Billion0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$810 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.7B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...